	US 12,128,094 B2
	Immunogenic compositions comprising OMVs, an acellular pertussis antigen, a tetanus toxoid and a diphtheria toxoid
Mario Contorni, Siena (IT); Mariagrazia Pizza, Siena (IT); and Anja Seubert, Siena (IT)
Assigned to GlaxoSmithKline Biologicals SA, Rixensart (BE)
Appl. No. 17/287,268
Filed by GLAXOSMITHKLINE BIOLOGICALS SA, Rixensart (BE)
PCT Filed Nov. 4, 2019, PCT No. PCT/EP2019/080120 § 371(c)(1), (2) Date Apr. 21, 2021, PCT Pub. No. WO2020/094580, PCT Pub. Date May 14, 2020.
Claims priority of application No. 18204691 (EP), filed on Nov. 6, 2018.
Prior Publication US 2023/0201325 A1, Jun. 29, 2023
Int. Cl. A61P 31/04 (2006.01); A61K 39/00 (2006.01)

CPC A61K 39/0018 (2013.01) [A61P 31/04 (2018.01); A61K 2039/55505 (2013.01)]

19 Claims

1. An immunogenic composition comprising (a) Outer Membrane Vesicles (OMVs), (b) an acellular pertussis antigen, (c) a tetanus toxoid and (d) a diphtheria toxoid, wherein the OMVs are derived from a Bordetella pertussis strain comprising an S1 gene which has been modified to include the mutations R9K and E129G and which expresses a genetically detoxified pertussis toxoid PT 9K/129G;

wherein the OMVs are not treated or chemically detoxified by treatment with formaldehyde, formalin, glutaraldehyde, hydrogen peroxide or a combination thereof.